Trial Profile
Biomarkers, breast density and risk reduction perspectives in BRCA carriers
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Deslorelin (Primary) ; Estradiol (Primary) ; Testosterone (Primary)
- Indications Breast cancer
- Focus Biomarker; Therapeutic Use
- 29 Jan 2024 Planned End Date changed from 15 Dec 2023 to 15 Mar 2024.
- 29 Jan 2024 Planned primary completion date changed from 15 Dec 2023 to 15 Mar 2024.
- 03 Aug 2023 Planned End Date changed from 15 Jun 2023 to 15 Dec 2023.